Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
About the study
This study will be used to determine the safety and tolerability of BMS-986016 administered alone and in combination with Nivolumab in subjects with advanced solid tumors.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Must have histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable)
- Must have received, and then progressed or been intolerant to, standard treatment regimen in the advanced or metastatic setting, if such a therapy exists
- Presence of at least one lesion with measurable disease as defined by RECIST v1.1 criteria for response assessment
- Males and Females, ages 20 years or older, inclusive
EXCLUSION CRITERIA
Exclusion Criteria:
- Known or suspected CNS (central nervous system) metastases or with the CNS as the only site of active disease
- Other concomitant malignancies (with some exceptions per protocol)
- Any active autoimmune disease or history of known or suspected autoimmune disease
- History of uncontrolled or significant cardiovascular disease
Other protocol defined inclusion/exclusion criteria could apply
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Cancer
Age (in years)
20+
Phase
Phase 1
Participants needed
35
Est. Completion Date
Sep 8, 2023
Treatment type
Interventional
Sponsor
Bristol-Myers Squibb
ClinicalTrials.gov identifier
NCT02966548
Study number
CA224034
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?